Clinical trial
Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00002786 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002786 |
|---|---|
| Title | Biological Therapy in Treating Patients With Metastatic Melanoma |
| Official title | PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY USING GENETICALLY MODIFIED AND UNMODIFIED AUTOLOGOUS CD8+ TYROSINASE-SPECIFIC T CELLS FOR PATIENTS WITH METASTATIC MELANOMA |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, therapeutic tumor infiltrating lymphocytes |
| Enrollment | 20 |
| Start date | Oct 1, 1995 |
| Completion | Mar 1, 2006 |
| First posted | May 26, 2003 |
| Last update posted | May 10, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: